Redcare Pharmacy’s Tech-Driven Turnaround Faces a Margin Reality Check

Redcare Pharmacy’s stock has clawed back from a March low of 31 euros, now trading around 53 euros, yet it remains down roughly 20% for the year. This partial recovery underscores the complex battle the German online pharmacy is fighting: leveraging technological leadership and prescription dominance to offset fierce competition and severe margin pressure.

A key strategic move came with the company becoming the first pharmacy to integrate a new access solution for Germany’s Telematics Infrastructure (TI 2.0). Developed with partners ehex and D-Trust, this HSM-B technology replaces mandatory physical institution cards with a fully digital identity. The upgrade aims to accelerate e-prescription processing by reducing wait times in the CardLink redemption process and is expected to create a leaner, more scalable cost structure over time.

Operationally, the first quarter of 2026 provided a strong foundation. Group revenue hit 848 million euros, an 18% year-on-year increase that sits at the top end of the annual guidance. This was powered by a 35% surge in the prescription (Rx) segment, while the German non-prescription (OTC) business recovered to about 10% growth.

However, this robust top-line performance exists alongside significant strategic threats, particularly in the OTC arena. The competitive landscape intensified in late 2025 when drugstore chain dm launched its “dm-med” online platform. Rival Rossmann has also announced building its own online pharmacy as a core project for this year, though it has stated it will not offer prescription medicines. This structural protection for Redcare’s Rx business is critical, as the company holds a commanding 67% market share in the German online prescription market and expects Rx revenues to exceed 670 million euros in 2026.

The assault on the OTC segment has forced management to recalibrate. The mid-term margin target for this business has been revised down from over 8% to more than 5%. For the full year 2026, Redcare is targeting adjusted EBITDA margin of at least 2.5%, a goal reiterated ahead of the full Q1 report due on May 6th.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

This margin pressure coincides with the most expensive investment cycle in the company’s history. A new logistics center in Plzen, Czech Republic, is designed to increase annual capacity by 15 million parcels, but the associated capital expenditures have weighed on financial targets.

Leadership is undergoing a simultaneous renewal. At the Annual General Meeting on April 15th, shareholders elected a completely new supervisory board. Anja Hendel, Max Müller, and Peter Schmid von Linstow joined, replacing three members who had served since the 2016 IPO. The board is now chaired by Michael Köhler, with Schmid von Linstow as deputy. This new council immediately shares oversight with CFO Hendrik Krampe, who took office on December 1, 2025, bringing two decades of finance experience from fast-growing e-commerce firms, including eight years at Amazon.

Analyst perspectives reflect this dichotomy. Jefferies maintains a buy rating and a 150 euro price target, praising the strong start to the year. Deutsche Bank also recommends buying, citing Redcare’s growing e-prescription market share. Some analysts, like Felix Dennl from Bankhaus Metzler, point to potential structural tailwinds, arguing that proposed government increases to prescription co-payments could drive more price-sensitive patients toward cheaper online channels.

The company’s medium-term ambition is an adjusted EBITDA margin exceeding 5%, driven by automation and the expansion of higher-margin areas like its marketplace. The upcoming quarterly report will be the first test for the new supervisory board and CFO to defend their annual targets of 13-15% revenue growth and that crucial 2.5% margin, all while navigating a direct competitive onslaught in the OTC space.